Literature DB >> 19389716

Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.

Monika Schoels1, Daniel Aletaha, Josef S Smolen, Johannes W J Bijlsma, Gerd Burmester, Ferdinand C Breedveld, Maurizio Cutolo, Bernard Combe, Maxime Dougados, Paul Emery, Joachim Kalden, Edward C Keystone, Tore K Kvien, Emilio Martin-Mola, Carlomaurizio Montecucco, Maarten De Wit.   

Abstract

BACKGROUND: Therapeutic approaches to rheumatoid arthritis (RA) have undergone significant changes. The importance of tight control and early treatment, rapidly altered if goals are not achieved, is supported by evidence. However, it is unknown to what extent these insights are accepted by practitioners in clinical practice.
OBJECTIVE: To obtain information about standard follow-up and treatment practices, and rheumatologists' aims in the care of patients with RA.
METHODS: A survey conducted at the 2008 EULAR Congress.
RESULTS: Most specialists, who were mainly from Europe and Latin America, were well-informed about recent concepts: two-thirds specified remission as a major goal. The experts attempted to reach treatment aims within 12-14 weeks, altering treatment otherwise. Disease activity assessment by composite measures is performed by a majority, although one-third preferentially relied upon their judgment.
CONCLUSION: These results suggest the acceptance of ambitious treatment concepts in practice. Although voluntary surveys have limitations, the answers reflect widespread adoption of desirable standards of care.

Entities:  

Mesh:

Year:  2009        PMID: 19389716     DOI: 10.1136/ard.2009.108472

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Pharmacotherapy: How well can we compare different biologic agents for RA?

Authors:  Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2010-05       Impact factor: 20.543

2.  Treating rheumatoid arthritis to target: an international initiative.

Authors:  Elana J Bernstein; Jonathan Kay; Allan Gibofsky
Journal:  Curr Rev Musculoskelet Med       Date:  2011-09

3.  Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities.

Authors:  Emily J Bacalao; George J Greene; Jennifer L Beaumont; Amy Eisenstein; Azra Muftic; Arthur M Mandelin; David Cella; Eric M Ruderman
Journal:  Clin Rheumatol       Date:  2017-06-26       Impact factor: 2.980

4.  Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.

Authors:  Jeffrey R Curtis; Kristel Luijtens; Arthur Kavanaugh
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

6.  High disease activity may not be sufficient to escalate care.

Authors:  Liana Fraenkel; Meaghan Cunningham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

7.  Treating rheumatoid arthritis to target: recommendations assessment questionnaire in Korea.

Authors:  Yong-Beom Park; Eun-Mi Koh; Ho-Youn Kim; Sung-Hwan Park; Won Park; Sang Choel Bae; Yeong-Wook Song; Dae-Hyun Yoo; Bin Yoo; Soo-Kon Lee
Journal:  Clin Rheumatol       Date:  2013-09-13       Impact factor: 2.980

8.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

Review 9.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.